Skip to Content

Triheptanoin Approval Status

FDA Approved: No
Generic name: triheptanoin
Company: Ultragenyx Pharmaceutical Inc.
Treatment for: Long-Chain Fatty Acid Oxidation Disorders

Triheptanoin is a synthetic triglyceride compound in development for the treatment of long-chain fatty acid oxidation disorders.

Development Status and FDA Approval Process for triheptanoin

Aug  1, 2019Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
Apr 23, 2015Ultragenyx Granted Additional Orphan Drug Designations for Triheptanoin
Dec 17, 2013Ultragenyx Investigational New Drug Application for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome is in Effect

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.